Bicara Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)Director and Officer Trading Plans and Arrangements
The following table describes for the three months ended March 31, 2025 each trading arrangement under which the Company’s directors or officers adopted, materially modified, orterminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangements | Nature of Trading Arrangements | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Claire Mazumdar (Chief Executive Officer) | Adoption (February 12, 2025) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of a) June 17, 2026; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan. | Up to 270,000 shares |
| Ryan Cohlhepp (President and Chief Operating Officer) | Adoption (February 12, 2025) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of a) June 15, 2026; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan. | Up to 180,500 shares |
| Ivan Hyep (Chief Financial Officer ) | Adoption (February 13, 2025) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of a) June 20, 2026; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan. | Up to 165,400 shares |
| David Raben (Chief Medical Officer ) | Adoption (February 12, 2025) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of a) June 24, 2026; b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and c) the date on which the plan holder gives notice to terminate the plan. | Up to 104,000 shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.